natgillin/translations-raw huggingface dataset:
the cytotoxin is selected from the group of cytotoxins depicted below: and wherein R1= alkyl, aryl, alkoxy, aryloxy, R2, R3= alkyl, aryl the effector moiety is linked through an oxime or hydrazone linkage to a saccharide residue of the glycan; and the effector moiety is linked through an oxime or hydrazone linkage to a saccharide residue of the glycan, wherein the saccharide residue is a terminal sialic acid or galactose residue of the glycan. 
>E FI o pri čemu Ri= alkil, aril, alkoksi, ariloksi, R2, Rs= alkil, aril b) = efektorski dio je povezan preko vezanja oksima ili hidrazona na saharidni ostatak glikana; i Cc) efektorski dio je povezan preko vezanja oksima ili hidrazona na saharidni ostatak glikana, pri čemu saharidni ostatak je terminalna sialinska kiselina ili galaktozni ostatak glikana.
A compound of any one of claims 1-4 for use in a method for treatment, management or prevention of a disease or disorder, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, hemoglobinopathy or a related disorder, or a TNFa related disorder. 
Spoj s formulom (IV): [image] ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer naznačen time da je za uporabu u postupku za liječenje, upravljanje ili prevenciju bolesti ili poremećaja, pri čemu bolest ili poremećaj je bolest ili poremećaj povezan s neželjenom angiogenezom; bol; makularna degeneracija; kožna bolest; plućni poremećaj; poremećaj vezan uz azbest; parazitska bolest; poremećaj imunodeficijencije; CNS poremećaj; ateroskleroza; disfunkcionalni san; ili hemoglobinatija, pri čemu:
and R2 independently represent a hydrogen atom, halogen, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl or a C1-6alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C3-C7 cycloalkyl, NR6R7, OR6, S(O)nR6 (where n is 0, 1 or 2); or 
R' i R* neovisno jedan o drugome predstavljaju atom vodika, halogen, C»-C4 alkenil, C2-Cg alkinil, C,-C, cikloalkil ili Crgalkil skupina, pri čemu su potonje četiri skupine opcionalno supstituirane s jednim ili više supstituenata koji se neovisno odabiru iz skupine koju sačinjavaju halogen, C;-C; cikloalkil, NR"R/, OR", S(O),R" (pri čemu je n 0, 1 ili 2); ili
A method according to claim 3, wherein the sludge is treated with said superheated steam for 20 to 30 minutes. 
Metoda u skladu s patentnim zahtjevom 3, karakterizirana tretiranjem mulja superzagrijanom parom tijekom 20 do 30 minuta.
The method of claim 24 wherein the condition is heart failure. 
Spoj patentnog zahtjeva 10 gdje je stanje kardiovaskularna bolest ili srčana insuficijencija.
A prodrug selected from the group consisting of: wherein m is an integer from 200 to 250 and n is an integer from 100 to 125; 
Predlijek, naznačen time, da je odabran iz skupine koju čine: pri čemu je m cijeli broj od 200 do 250, dok je n cijeli broj od 100 do 125;
The oil was purified using preparative HPLC (Column: Lichrospher Si60, 5 µm, 250 x 21.20 mm, mobile phase: hexane: ethanol: dichloromethane (85:15:5); UV 254 nm, flow: 10 ml min-1) at 350 mg per injection followed by concentration of the fractions of interest under vacuum. 
Ulje se pročisti uporabom preparativne HPLC (kolona: Lichrospher Si60, 5 um, 250 x 21.20 mm, mobilna faza: heksan: etanol: diklorometan (85:15:5); UV 254 nm, protok: 10 ml min') uz 350 mg po injiciranju nakon čega slijedi koncentriranje poželjnih frakcija uz vakuum.
The present invention provides vesicles that are characterized by comprising epidermal growth factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. 
HR P20170145 T1 PATENTNI ZAHTJEVI m m Čestice koje sadrže epidermalni faktor rasta (EGF), kationski surfaktant i kolesterol ili njihove derivate.
wherein each of said R4a, R4b, and R4c heterocyclic and heteroaryl ring system is optionally substituted with up to four fluorine atoms, up to two C1-4 alkyl, up to two OH groups, a C(O)C1-4 alkyl, a C(O)OC1-4 alkyl, or a C(O)OC0-4 alkyl-C3-5 cycloalkyl; and wherein each of said R4a, R4b, and R4c alkyl and cycloalkyl is optionally substituted with up to 2 non-geminal OH groups or up to 3 fluorine atoms. 
pri čemu je svaki od navedenog R4a, R4b, i R4c heterocikličnog i heteroaril sistema prstena izborno supstituiran sa do četiri atoma fluora, do dva C1-4 alkila, do dvije OH grupe, C(O)C1-4 alkila, C(O)OC1-4 alkila, ili C(O)OC0-4 alkil-C3-5 cikloalkila; i pri čemu svaki od navedenih R4a, R4b, i R4c alkila i cikloalkila je izborno supstituiran sa do 2 negeminalne OH grupe ili do 3 atoma fluora.
A syrup containing 1% (weight per volume) of active substance was prepared from the following ingredients: 
Sirup koji sadrži 1 % (težinski na volumen) aktivne supstancije dobiven je iz slijedećih komponenata:
The invention aims to remedy these disadvantages by providing a sanding element with a much longer life than the present sanding elements, while it allows to finish a workpiece almost to perfection in a very fast manner, as a result of which the use of two different discs is no longer necessary. 
Ovaj izum ima za cilj da se poprave ovi nedostaci i on osigurava element za brušenje s mnogo duljom životnom dobi nego što je imaju sadašnji elementi za brušenje, dok isto tako omogućava da se komad koji se obrađuje završno obradi do savršenstva na vrlo brz način, a kao rezultat toge je to, da više nisu potrebna dva različita diska.
an inlet (5) for the gas stream from a gasifier, 
- ulaz (5) za struju plina iz rasplinjača,
a carbomer physiologically-compatible alkali or alkaline earth metal carbonate and/or hydrogen carbonate, wherein said tamarind extract is a dried aqueous or water-alcohol extract from the plant seeds having a titrated polysaccharide xyloglucan content of at least 30% by weight. 
- < karbonat i/ili hidrogenkarbonat fiziološki kompatibilnog alkalijskog ili zemnoalkalijskog metala, pri čemu rečeni ekstrakt tamarinda jest sušeni vodeni ekstrakt ili ekstrakt vode-alkohola iz sjemenki biljke koje imaju titriran sadržaj polisaharid-ksiloglukana od najmanje 30% po masi.
A method for determining an immune response in a subject, comprising determining T cells reactive with a peptide of any one of items 1 to 3 in a biological sample isolated from the subject. 
Postupak za određivanje imunološkog odgovora kod subjekta, koji obuhvaća određivanje T stanica reaktivnih s peptidom sukladno patentnom zahtjevu 1 ili 2 u biološkom uzorku izoliranom od subjekta.
Device as in any of claims 7-10, characterised in that the flat upper guiding surface (24a) of the chamber (18) runs into the lower curved guiding surface with a steeper guiding surface section. 
Naprava u skladu s bilo kojim od patentnih zahtjeva 7-10, naznačena time što ravna gornja površina za vođenje (24a) komore (18) prema donjoj zakrivljenoj površini za vođenje strmijim dijelom površine za vođenjo.
A corn plant, or seed, or product derived from the plant or seed MON89034 wherein the genomic DNA comprising comprises a DNA molecule consisting essentially of SEQ ID NO:5 and complements thereof. 
Biljka kukuruza otporna na insekte, ili dijelovi iste, ili sjeme iste, ili potomstvo iste prema zahtjevu 1 sadrže nukleotidnu sekvencu SEQ ID NO:5.
A process according to claim 1 wherein the polymeric shell of the microcapsule is obtainable by polycondensation or by reacting the second monomeric component formed in situ with the first monomeric component. 
Postupak prema zahtjevima 1-11 naznačen time da polimerna ovojnica mikrokapsule se može dobiti reakcijom prve monomerne komponente s drugom monomernom komponentom interfacijalnom polimerizacijom pomoću polikondenzacije ili reakcijom druge monomerne komponente nastale in silu s prvom monomernom komponentom.
The process according to item 10, wherein the boronic acid in step (A) is a substituted or unsubstituted phenyl boronic acid. The process according to either item 10 or 11, wherein the boronic acid in step (A) is a phenyl boronic acid substituted with one or more units independently chosen from: 
A HO cRčk IĆ FI Postupak prema zahtjevu 1, gdje boronska kiselina u koraku (A) jest supstituirana ili nesupstituirana fenil boronska kiselina; i/ili gdje boronska kiselina u koraku (A) jest fenil boronska kiselina gdje R'" predstavlja jednu ili više supstitucija za vodik nezavisno izabranih između: 1)
at least one controller that dynamically controls at least one of a temperature or a cooking time for at least one of the ovens in response to a dynamically updated estimated transit time of the vehicle to a delivery destination for delivery of the contents of the respective oven. 
radio uređaj koji je komunikacijski spojen s najmanje jednom upravljačkom jedinicom (222) za proizvodnju signala koji pokazuju najmanje jednu dinamički ažuriranu temperaturu i/ili jedno dinamički ažurirano vrijeme kuhanja za barem jedan od štednjaka (210), gdje se signali zaprimaju iz udaljenog stacioniranog izvora (102).
The process of claim 7, wherein said solution is heated to a temperature of from 70°C. to 85°C. before the ferric ion source is added and maintained at a temperature of from 70°C to 85°C after the ferric ion source is added and until complete dissolution of the ferric ion source has occurred. 
Postupak prema zahtjevu 7, gdje se otopina zagrijava do temperature od do prije nego što se doda izvor feri iona i održava na temperaturi od do nakon što se doda izvor feri iona i dok ne dođe do potpunog otapanja izvora feri iona.
However references to individual alkyl groups such as "propyl" are specific for the straight-chain version only, references to individual branched-chain alkyl groups such as "isopropyl" are specific for the branched-chain version only and references to individual cycloalkyl groups such as "cyclopentyl" are specific for that 5-membered ring only. 
Međutim, navođenje pojedinačnih alkilinih skupina, poput "propila" odnosi se samo na narazgranate verzije, navođenje pojedinačnih razgranatih alkilinih skupina, poput "isopropila" odnosi se samo na razgranate verzije i navođenje pojedinačnih cikloalkilnih skupina, poput "ciklopentila" odnosi se samo na peteročlani prsten.
The catheter as claimed in claim 3, wherein the elbow portion (5) is positioned at an angle of 50 [deg.] to 90 [deg.] relative to the catheter tube. 
Kateter prema zahtjevu 3, pri čemu je koljenasti dio (5) postavljen pod uglom od 50 stupnjeva do 90 stupnjeva u odnosu na cijev katetera.
A is selected from the group consisting of R5 is independently selected from the group consisting of alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, NRCRD, and (NRCRD)carbonyl; n is 0, 1, 2, or 3; 
R; je neovisno odabran iz skupine koja se sastoji od alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, haloalkoksi, haloalkila, halogena hidroksi, hidroksialkila, NRcRp i (NReRp)karbonila; n je 0, 1, 21li 3;
The terminal apparatus according to one of claims 1 to 4, wherein when one cluster is allocated, the resource allocation information is signaled using the available bits only; and the controller determines the resource allocation information based on the available bits. 
Uređaj za prijenos prema jednom od zahtjeva 1 do 5, naznačen time da kad se dodjeljuje jedan klaster, podatak o dodjeli resursa signalizira se korištenjem dostupnih bitova u polju dodjele resursa isključivo.
and R'1 are the same or different, and each represents an aryl group, a heteroaryl group, or R1 and R'1, together with the carbon atom to which they are linked, form a fused ring structure of formula: in which A represents a single bond, a methylene group, a dimethylene group, oxygen, nitrogen or sulphur, said sulphur optionally being in the sulphoxide or sulphone forms, 
R; 1 R', su isti ili različiti, te svaki predstavlja arilnu skupinu, heteroarilnu skupinu, ili R, i R',, zajedno sa atomom ugljika na koji su vezani, formiraju kondenziranu prstenastu strukturu formule:
A method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia comprising administering to the subject an effective amount of a compound according to claim 1 . The method of claim 8, wherein the compound is: 
Spoj ili sol prema patentnom zahtjevu 5 naznačen time što je za upotrebu u postupku liječenja ili smanjenja intenziteta boli kod subjekta s kroničnom boli, crijevnom boli, neuropatskom boli, mišićno-skeletnom boli, akutnom boli, upalnom boli, boli zbog raka, idiopatskom boli, boli nakon kirurške intervencije, visceralnom boli, boli zbog multiple skleroze, Charcot-Marie-Tooth sindroma, inkontinencije, patološkog kašlja ili srčane aritmije.
at least one further therapeutic agent selected from the group of chemotherapeutic agents, radiotherapeutic agents, surgery agents, immunotherapeutic agents, probiotics and antibiotics, wherein said active ingredients are formulated for separate, simultaneous, or combination therapy, in particular for combined or sequential use. 
najmanje jedno dodatno terapeutsko sredstvo izabrano iz grupe kemoterapijskih sredstava, radioterapijskih sredstava, kirurških sredstava, imunoterapijskih sredstava, probiotika i antibiotika, pri čemu su navedeni aktivni sastojci formulirani za posebnu, istovremenu ili kombiniranu terapiju, naročito za kombiniranu ili uzastopnu uporabu.
The method according to claim 9, wherein the identifying of the predetermined direction is accomplished by locating an orienting member in a position of lowest gravitational potential energy. 
Uređaj (100) za servisiranje kanala bušotine sukladno Zahtjevu 1, naznačen time da je orijentirajući članak (244) selektivno pričvršćen u položaj najniže gravitacijske potencijalne energije.
An oven-dried reflux condenser, purged with N2, was placed on top of the flask and it was put in an oil bath heated to 75° C. The BOM acyl fluoride, Formula 45 (0.5 g, 1.31 mmol), in toluene (1 mL) was added to the flask and the temperature increased to 85° C. Stirring continued under N2 for 5.5 hour to give product of Formula 46. 
U pećnici osušen refluksni kondenzator, koji je bio pročišćen s No, bio stavljen na vrh tikvice i ona je bila stavljena u uljnu kupelj koja je bila zagrijana do 75*C. BOM acil fluorid, formula 45 (0.5 g, 1.31 mmol), u toluenu (1 mL) bio je dodan u tikvicu i temperatura je porasla do 85"C. Miješanje je nastavljeno pod N2 5.5 sati da bi se dobio produkt formule 46.
The pharmaceutical dosage form according to claim 7, which contains the second pharmacologically active ingredient in a dose of from 0.05 to 5 g. 
Farmaceutski oblik doziranja za uporabu za sprječavanje ili liječenje boli prema zahtjevu 7 ili 8, naznačen time da sadrži drugi farmakološki aktivni sastojak u dozi od 0.05 do 5 g.
The precipitate is filtered, washed with water and dissolved in chloroform (400 ml). 
Talog se odfiltrira, ispere s vodom 1 otopi u kloroformu (400 ml).
In some embodiments, the composition of the invention is for use in a method of reducing the level of Enterobacteriaceae in the gastrointestinal tract in a subject having an increased level of hydrogen in their breath relative to a healthy subject. 
(c) u postupku liječenja konstipacije pri čemu subjekt ima konstipaciju bez dijareje Kompozicija za upotrebu prema bilo kojem prethodnom zahtjevu, gdje subjekt ima dodatno abdominalnu bol i/ili krvarenje i/ili gdje subjekt zma povećanu razinu vodika u njegovom dahu, u odnosu na zdravi subjekt.
The crude was re-crystallized from EtOH. 
Krutina se rekristalizira iz EtOH.
The nasal spray device of claim 1, wherein the transfer channel has a circular cross-section. 
Nazalni raspršivač za nos sukladno bilo kojem prethodnom zahtjevu, pri čemu prijenosni kanal (13) ima kružni poprečni presjek.
a refractory defining the casting channel and forming the sliding face (19a, 20a). 
-vatrostalni materijal koji određuje kanal za lijevanje 1 tvori kliznu površinu (194, 20a).
The method according to claim 1, wherein said speed controller (20) provides a torque control signal to said drive system (15), and wherein said torque provided by said drive system (15) is varied by applying a torque control signal having a time-varying signal frequency, in particular an exponentially varying signal frequency over a set time interval. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni regulator brzine (20) šalje signal za reguliranje okretnog momenta u navedeni pogonski sustav (15), te gdje se navedeni okretni moment kojeg osigurava navedeni pogonski sustav (15) mijenja primjenom signala za reguliranje okretnog momenta s vremenski promjenjivom frekvencijom signala, osobito s ekponencijalno promjenjivom frekvencijom signala, tijekom podešenog vremenskog intervala.
A compound of formula (IV) as claimed in claim 1 or claim 2, wherein wherein D is N(Rh), and Ar1 and Ar2 are substituted or unsubstituted triazine, pyrimidine, pyridine, oxazole, 2,4-difluorophenyl, Cl-phenyl or fluorophenyl. 
Spojevi formule (IV) prema zahtjevu 1 ili 2, naznačeni time, da D je N(Rh), a Ar1 i Ar2 su supstituiran ili nesupstituiran fenil ili het, gdje je spomenuti het supstituiran ili nesupstituiran triazin, pirimidin, piridin, oksazol, 2,4-difluorofenil, Cl-fenil ili fluorofenil.
exposing a corn plant containing a chromosome comprising SEQ ID NO: 1, a heterologous transgene insert, and SEQ ID NO:2 to one or more recombination-inducing agents, wherein said heterologous transgene insert comprises a selectable marker gene and a truncated rice actin promoter that is operably linked to a cspB gene; 
Sastav obuhvaća polinukleotidnu sekvencu koja je dijagnostička za prisutnost MON87460 DNK, pri čemu polinukleotid ima sekvencu navedenu u SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, ili SEQ ID NO: 25.
Histamine H3 Receptor-Mediated Response 
Odgovor posredovan histaminskim H3 receptorom
The double stranded RNAi agent of claim 6, wherein the RNAi agent is conjugated to the ligand as shown in the following schematic wherein X is O or S. 
Dvolančano RNAi sredstvo prema zahtjevu 6, naznačeno time da je RNAi sredstvo konjugirano na ligand kako je prikazano u slijedećoj shemi [image] pri čemu X je O ili S.
A composition for use in treating partial seizure comprising cannabidiol (CBD). 
Spoj za primjenu u liječenju parcijalnih napadaja koji sadrži kanabidiol (CBD).
The use according to claim6, wherein the composition is administered by a route selected from injection, topical application or the oral route, over a period of time and in an amount, which is effective to treat or prevent the neuropathic condition. 
Uporaba prema zahtjevu 7, naznačena time da se pripravak daje načinom davanja koji je odabran od injekcije, topikalne primjene ili oralnim načinom, kroz period vremena i u količini, koja je učinkovita za liječenje ili sprečavanje neuropatske boli.
The method according to claim 1, wherein the production interval between successive strippings of adhesive coating from the drying cylinder is at least about 7 hours. 
Metoda u skladu s patentnim zahtjevom 2, pri čemu je proizvodni interval između sljedećeg skidanja adhezivne obloge s cilindra za sušenje (80) najmanje oko 7 sati.
For obtaining sufficient force to press the cup wall and shell wall together until the thermo-sealable plastic coating is again hardened, an annular first member with at least one radially displaceable or protruding pressing element can be positioned inside the cup body, which pressing element presses against an external second member to press the walls of cup body and shell together by both members to form the bonding spots and/or bonding areas. 
Za dobivanje dovoljne sile koja stišće zajedno stijenku čaše i stijenku ljuske sve dok se opet ne stvrdne obloga od plastike koja se može lijepiti kada je vruća, u tijelo čašu se stavi prvi prstenasti element s najmanje jednim tlačnim elementom koji tlačni element se može pomicati ili izbočiti, pri čemu se navedeni tlačni element pritisne na drugi vanjski element, da bi se uz pomoć oba elementa stisnute zajedno stijenke tijela čaše i ljuska, kako bi se stvorila jedna točka spajanja ili više točaka spajanja, odnosno jedno područje spajanja ili više područja spajanja.
As the SDS concentration drops below about 95 µg/mg, however, the size of microaggregates rises sharply (Figure 1), rising from an average of ~60 IL-2 molecules per aggregate at 95µg/mg to an average of~180 at 75µg/mg. 
Kako koncentracija SDS pada ispod oko 9%5ug/mg, ipak veličina mikroagregata raste oštro (Slika 1), rastući od prosječno -60 molekula IL-2 po agregatu kod 95ug/mg do prosječno >180 kod 75ug/mg.
The method according to any of the preceding embodiments, wherein the RNA comprises a linear sequence of at least 1,000 nucleotides e.g. at least 5,000 nucleotides. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što RNA sadrži linearni slijed od najmanje 1000 nukleotida, primjerice najmanje 5000 nukleotida.
A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation which is cured at a temperature of at least about 60 °C for a time period of at least about 1 minute, the extended release matrix formulation comprising a composition comprising at least: 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1, naznačen time da formulacija matrice s produljenim otpuštanjem kada je podvrgnuta indentacijskom testu ima „dubinu prodiranja s razmakom pukotine“ od barem oko 1.0 mm.
The abnormal protein triggers a process that results in the death of neurons in the corpus striatum region of the brain, possibly by the clumping or aggregation of the abnormal protein inside many types of neurons. 
Abnormalan protein djeluje kao okidač procesa koji rezultira odumiranjem neurona u području mozga corpus striatum, vjerojatno zbog gomilanja ili agregacije abnormalnog proteina unutar mnogih tipova neurona.
R5a is hydrogen, lower alkyl optionally substituted by substituent group C, carbocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, carbocycleoxy lower alkyl optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, heterocycle lower alkyl optionally substituted by substituent group C, heterocycleoxy lower alkyl optionally substituted by substituent group C, —Y—S—RD1, 
R" je niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbocikloksi niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, ili